CN1213733C - Method of preparing stable suspension of insoluble microparticles - Google Patents
Method of preparing stable suspension of insoluble microparticles Download PDFInfo
- Publication number
- CN1213733C CN1213733C CNB998156442A CN99815644A CN1213733C CN 1213733 C CN1213733 C CN 1213733C CN B998156442 A CNB998156442 A CN B998156442A CN 99815644 A CN99815644 A CN 99815644A CN 1213733 C CN1213733 C CN 1213733C
- Authority
- CN
- China
- Prior art keywords
- surface modifier
- phospholipid
- micron
- preparation
- mean particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000725 suspension Substances 0.000 title claims abstract description 6
- 238000000034 method Methods 0.000 title claims description 22
- 239000011859 microparticle Substances 0.000 title 1
- 239000003607 modifier Substances 0.000 claims abstract description 70
- 239000003814 drug Substances 0.000 claims abstract description 25
- 239000002245 particle Substances 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 150000003904 phospholipids Chemical class 0.000 claims description 35
- -1 fatty acid esters Chemical class 0.000 claims description 31
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000004094 surface-active agent Substances 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 10
- 239000001294 propane Substances 0.000 claims description 10
- 229920001400 block copolymer Polymers 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 6
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 208000028017 Psychotic disease Diseases 0.000 claims description 6
- 239000001961 anticonvulsive agent Substances 0.000 claims description 6
- 229960003965 antiepileptics Drugs 0.000 claims description 6
- 235000010445 lecithin Nutrition 0.000 claims description 6
- 239000000787 lecithin Substances 0.000 claims description 6
- 229940067606 lecithin Drugs 0.000 claims description 6
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 5
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 5
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 5
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 5
- 239000004531 microgranule Substances 0.000 claims description 5
- 229920000570 polyether Polymers 0.000 claims description 5
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 3
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 3
- 229940035676 analgesics Drugs 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 239000000730 antalgic agent Substances 0.000 claims description 3
- 230000003288 anthiarrhythmic effect Effects 0.000 claims description 3
- 230000001466 anti-adreneric effect Effects 0.000 claims description 3
- 230000001078 anti-cholinergic effect Effects 0.000 claims description 3
- 230000001773 anti-convulsant effect Effects 0.000 claims description 3
- 230000001430 anti-depressive effect Effects 0.000 claims description 3
- 230000003556 anti-epileptic effect Effects 0.000 claims description 3
- 230000000843 anti-fungal effect Effects 0.000 claims description 3
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 229940125713 antianxiety drug Drugs 0.000 claims description 3
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 3
- 239000000935 antidepressant agent Substances 0.000 claims description 3
- 229940005513 antidepressants Drugs 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 239000002249 anxiolytic agent Substances 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 238000010612 desalination reaction Methods 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 230000005934 immune activation Effects 0.000 claims description 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 3
- 230000001861 immunosuppressant effect Effects 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 239000003149 muscarinic antagonist Substances 0.000 claims description 3
- 210000002569 neuron Anatomy 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 3
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 3
- 229940067626 phosphatidylinositols Drugs 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 239000008347 soybean phospholipid Substances 0.000 claims description 3
- 229940125725 tranquilizer Drugs 0.000 claims description 3
- 239000003204 tranquilizing agent Substances 0.000 claims description 3
- 230000002936 tranquilizing effect Effects 0.000 claims description 3
- 230000001713 cholinergic effect Effects 0.000 claims 2
- 230000000147 hypnotic effect Effects 0.000 claims 2
- 238000007789 sealing Methods 0.000 claims 1
- 230000003019 stabilising effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 9
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 239000012736 aqueous medium Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 48
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 229960001265 ciclosporin Drugs 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 229920001993 poloxamer 188 Polymers 0.000 description 5
- 229960001661 ursodiol Drugs 0.000 description 5
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 4
- 101100235626 Caenorhabditis elegans hlb-1 gene Proteins 0.000 description 4
- 229930105110 Cyclosporin A Natural products 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 4
- 229920002359 Tetronic® Polymers 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 229940044519 poloxamer 188 Drugs 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 229920001987 poloxamine Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 229920002517 Poloxamer 338 Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 230000000718 cholinopositive effect Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000003317 industrial substance Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Sub-micron and micron-size stable particles of water-insoluble or poorly soluble drugs or other industrially useful insoluble compounds suspended in an aqueous medium containing at least one surface modifier are prepared by selecting the surface modifier or modifiers such that the hydrophile-lipophile balance (HLB) of the composition, defined as formula (I): is between 4 and 9. This provides a reliable HLB-based selection criteria for selecting the type and amount of surface modifiers used to obtain sub-micron size stable suspensions.
Description
The present invention relates to produce the compositions and the method for submicron and micron big or small stable particle, this granule is water insoluble or is slightly soluble in medicine or other insoluble compound with industrial application value of water.The present invention provides reliably first based on the choice criteria of HLB, uses this standard can select to be used to obtain kind and the consumption of the surface modifier of submicron stable suspension.
Background of the present invention
People have proposed various schemes, attempt to adopt surface modifier to prepare the insoluble drugs prescription in aqueous solution, and the surface modifier that is adopted is the conjugate such as independent phospholipid or phospholipid and one or more surfactants.Yet, do not deliver the standard of any selection feature and consumption.United States Patent (USP) 5,145,684 have described a kind of microsolubility medicine, and it contains and is adsorbed on its surperficial non-crosslinked surface modifier.The amount of surface modifier is 0.1%-90% (weight), and the gained granular size is less than 400nm.United States Patent (USP) 5,298,262,5,326,552,5,336,507,5,340,564 and 5,470,583 have described the application of cloud point modifier, and microsolubility medicine wherein or diagnostic agent are adsorbed on its surface with cloud point modifier and non-crosslinked ion-type surface modifier.Cloud point modifier it is said the cloud point that can improve surfactant, thereby the growth of granular size can not appear in the gained nano-particle when carrying out heating disinfection for 121 ℃.These patents provide the example of the various specific cloud point modifier that are used in combination with the different surfaces activating agent, and wherein cloud point modification surfactant is optional.
WO 98/07414 has described a kind of microsolubility medicine, and it contains two kinds and is adsorbed on its surperficial surface modifier; With only compare with a kind of modifier, adding second surface modifier makes granular size reduce nearly 50%.
EP 0580690B1 has described with charged phospholipid and water-fast peptide has been carried out coating so that its solubilising, so the weight ratio of medicine and phospholipid is higher than a marginal value.Poloxamer 188 also is used to prepare drug particles when 0.01%-0.5% concentration.People observe, and when the concentration of poloxamer 188 increased, the ζ electromotive force significantly reduced.
United States Patent (USP) 5,091,187 have proposed to prepare injectable water-insoluble drug by the aqueous suspension that forms phospholipid coating microcrystal.Cause that by supersound process or other method of high shear force makes crystalline drug be reduced to 50nm-10 μ m in the presence of phospholipid.Phospholipid is used as unique surface modifier and is described.
United States Patent (USP) 5,858,410 by adopting piston clearance (piston-gap) homogenizer adding surfactant (synthetic or natural) to make the water-insoluble drug solubilising.The gained granule records its size for 10nm-1 through the photon correlation microscopy, 000nm, have account for sum less than its size of granule of 0.1% greater than 5 microns.Equally, surface modifier is chosen wantonly.
The present invention's narration
According to the compositions of the inventive method preparation, except water-insoluble or be slightly soluble in the drug particles and other industrial chemical compound of water, also comprise natural or synthetic phospholipid or the surfactant that uses separately, perhaps their uses that is bonded to each other.According to program of the present invention, with respect to the kind and the consumption of medicament selection surface modifier, so the system of this system hydrophilic-lipophile balance (HLB) value defined is as follows: system
System HLB value is in 4 to 9 scopes.When the HLB value was in this scope, the unit weight mean particle size of resulting product was less than about 1 micron, at each temperature and all show good stable in stress test.Used terminology is meant whole compositions in this description and claims, comprises that medicine, surface modifier, carrier, excipient, diluent and other are present in the component in this based composition usually.
Hydrophilic-lipophile balance (HLB) is the balanced proportions between two kinds of opposite trends that exist in the surfactant: hydrophilic (part that glassware for drinking water is had affinity) is to lipophile (part that oil is had affinity).The hydrophilic surfactant active is many more, and then HLB value high more (surpassing 10) when the HLB of surfactant value is 1-10, then is considered to have lipophile.The HLB value of surface modifier or surface modifier system is preferably between 5 to 35.
Chemical compound water insoluble or that be slightly soluble in water can be selected from various therapeutic agents, comprises antifungal, immunosuppressant or immune activation agent, antiviral agent, antitumor agent, analgesics or antiinflammatory, antibiotic, Anti-epileptics, anesthetis, sleeping pill, tranquilizer, psychosis, psychosis, antidepressant, antianxiety drugs, anticonvulsant, antagonist, neuron blocker, anticholinergic or cholinomimetic, antimuscarinic drug or muscarine medicine, antiadrenergic, antiarrhythmics, antihypertensive, hormone or nutrient.
Used surface modifier is divided into two classes substantially usually: phospholipid and surfactant.Phospholipid can be the phospholipid or the mixture of phospholipids of any natural generation, and sometimes this paper indication is " commerce " phospholipid, and for example lecithin or soybean phospholipid perhaps are used in combination them.Phospholipid can be desalination, hydrogenant or partially hydrogenated, and is perhaps natural, semisynthetic or synthetic.The example of the commercial phospholipid that obtains includes but not limited to lecithin P123 (Pfanstiehl), Lipoid E80 (lipid) and hydrogenated soya phosphatide Phospholipon 90H and 100H (Natterman) and 99% pure lecithin and S-PC (Avanti PolarLipids).The content of phospholipid is 0.01%-50% in the compositions, is preferably 0.05%-20%.
Surfactant is used as the second surface surface modifier sometimes, it comprises: (a) natural surfactant, for example casein, gelatin, tragakanta, wax, intestinal resin (enteric resins), paraffin, acacin, gelatin cholesterol ester and triglyceride; (b) nonionic surfactant, for example polyoxyethylene aliphatic alcohol ester, sorbitan fatty acid esters, polyoxyethylene fatty acid ester, sorbitan ester monostearin (sorbitan esters glycerolmonostearate), Polyethylene Glycol, hexadecanol, cetostearyl alcohol, octadecanol, poloxamer, poloxamines, methylcellulose, hydroxylated cellulose, hydroxypropyl cellulose, hydroxypropyl emthylcellulose, amorphous cellulose element, polyvinyl alcohol, polyvinylpyrrolidone and synthetic phospholipid; (c) colloidal clay, for example soap clay, fillite, colloidal silica.People Remington ' s Pharmaceutical Sciences in 1986 and Theory of Practice ofIndustrial Pharmacy such as Lachman are seen in detailed description about these surfactants.
The specific examples of suitable second surface modifier comprises: poloxamer, and as PLuronic
TMF68, F108 and F127, they are the oxirane of BASF production and the block copolymer of expoxy propane; Poloxamines is as the Tetronic of BASF production
TM908, it is the alkyl aryl polyether sulphonic acid ester Triton that produces by four functional blocks copolymers, Rohm and Haas that continuous adding oxirane and expoxy propane in ethylenediamine obtain
TMThe polyoxyethylene sorbitan fatty acid esters polysorbas20 that X-100, ICISpecialty Chemicals produce, 40,60 and 80, the Polyethylene Glycol Carbowax that produces of Union Carbide
TM3550 and 934; And HYDROXY PROPYL METHYLCELLULOSE and polyvinylpyrrolidone.
Surface modifier preferably polyoxyethylene sorbitan fatty acid esters, oxirane and expoxy propane block copolymer, Myrj 45, in ethylenediamine, add four functional blocks copolymers, alkyl aryl polyether sulphonic acid ester, Polyethylene Glycol, hydroxypropyl emthylcellulose and the polyvinylpyrrolidone that oxirane and expoxy propane obtain continuously.
Ideal surfactant is the block copolymer of polyoxyethylene sorbitan fatty acid esters, Myrj 45, oxirane and expoxy propane, add four functional blocks copolymers, alkyl aryl polyether sulphonic acid ester, Polyethylene Glycol, hydroxypropyl emthylcellulose and the polyvinylpyrrolidone that oxirane and expoxy propane obtain in ethylenediamine continuously.
Phospholipid can be that be desalted, that be hydrogenated or by partially hydrogenated, and is perhaps natural, semisynthetic, synthetic, preferably phosphatidylcholine, PHOSPHATIDYL ETHANOLAMINE, Phosphatidylserine, phosphatidylinositols, phosphatidyl glycerol or phosphatidic acid.
The preferred embodiment explanation
In order to further specify and describe selection course of the present invention, carried out following test.In an embodiment, use high pressure equipment under steady temperature and pressure premix to be handled, thereby make preparation be subjected to shear action, cavitation, impact and friction, this carries out in microcosmic fluidized bed plant or homogenizer.Details sees the following form.
Type of preparation | Processing machine | Total pass under the operating pressure | Average pressure (kPsi) | Mean temperature (℃) |
Cyclosporin A | Avestin C-50 homogenizer | 200 | 18 | 10 |
Ursodiol | Avestin C-5 homogenizer | 100 | 18 | 13 |
Benprofibratum | Microcosmic fluidized bed plant M110 EH | 50 | 18 | 5 |
" all over (pass) " is defined as the circulation of preparation by the machine each several part.Each machine " all over " or circulate as follows: Avestin C-50 homogenizer and Avestin C-5 homogenizer: preparation is placed on the inlet storage, flows to current again,, get back to the inlet storage then next through over-heat-exchanger.It is to make preparation be subjected to shearing force, cavitation, impact and friction by current.M110 EH: at first allow preparation through 20 times bypass circulation, it is defined as: the inlet storage arrives heat exchanger again to the aid in treatment assembly, gets back to the inlet storage then.Allow the gained preparation through loop, mutual chamber (interaction chember loop) again, it is defined as: the inlet storage arrives heat exchanger to the aid in treatment assembly again to mutual chamber (interaction chamber), gets back to the inlet storage then.It is to make preparation be subjected to shearing force, cavitation, impact and friction at mutual intracavity.After above-mentioned processing, each preparation is collected the phial of packing into, clog with rubbery stopper, the reuse aluminium lid covers, to be used for stability test.Acceptable granule is those microscopic particles in the 0.05-10 micrometer range.
Adopted following substances in an embodiment:
The abbreviated list of surface modifier | |
Full name | Abbreviation |
Lipid E-80 | LipE80 |
Phosphatidase 11 00H | Ph100H |
Myrj 52 | Myrj52 |
Tween 80 | Tw80 |
PLuronic F68 (being called poloxamer 188 again) | PF68 |
PLuronic F108 (being called poloxamer 338 again) | PF108 |
PLuronic F127 (being called poloxamer 407 again) | PF127 |
Tetronic 908 | T908 |
Supplier's list | |
Trade name | Supplier/place of production |
Cyclosporin A | North China drugmaker, China |
Ursodiol | Tokyo Tanabe, the Tokyo |
Benprofibratum | Laboratorio Chimico Internazionale s.p.a, Milan, ITA |
Lipid E-80 | Lipoid GMBH, Ludwigshafen, Germany |
Phosphatidase 11 00H | American Lecithin Company Natterman Phospholipids, Connecticut, U.S. Oxford |
Myrj52 | ICI, the Wilmington City, Delaware, USA State |
Tween 80 | ICI, Delaware, USA become the Er Mingdun city |
Tetronic and PLuronic block copolymer | BASF, New Jersey Mount Olive |
Following five kinds of different tests are used to assess stability of formulation.
Stability test | Explanation |
4 ℃ | Embodiment is stored in 4 ℃ (control temperature) |
25 ℃ | Embodiment is stored in 25 ℃ (control temperature, 60% relative humiditys) |
40 ℃ | Embodiment is stored in 40 ℃ (control temperature) |
Vibration | Under ambient room temperature embodiment is sidelong on the vibration table, hunting speed is 100rpm-110rpm. |
Thermal cycle | A circular definition is: embodiment stored 1-2 days down at 4 ℃, stored 1-2 days down at 40 ℃ again. |
If can satisfy at least two in the following condition, then said preparation is considered to stable:
(1) during 4 ℃ of following 4 weeks, mean particle size is less than 1.5 μ m.
(2) during 25 ℃ of following 4 weeks, mean particle size is less than 1.5 μ m.
(3) during 40 ℃ of following 1 weeks, mean particle size is less than 2.5 μ m.
(4) through after the vibration in 7 days, mean particle size is less than 1.5 μ m.
(5) through after 3 thermal cycles, mean particle size is less than 1.5 μ m.
Embodiment A
In this embodiment, assessed of the influence of system HLB value to the granular size and the stability of Cyclosporin A microgranule.We find to make system HLB value greater than 9 o'clock, gained preparation instability when phospholipid is used in combination with a kind of surface modifier.Yet when selecting system HLB value less than the combination of 9 (but greater than 0) for use, the gained preparation is a sub-micron, is stable.There is not the controlled trial of surface modifier to be used as with reference to having comprised yet.
Table 1.1 Cyclosporin A 5%w/w
Embodiment | No. 1, surface modifier | No. 2, surface modifier | Size (μ m) | Pass | System HLB | ||||
Kind | %w/w | HLB | Kind | %w/w | HLB | ||||
1 | - | - | 0 | - | - | 0 | 8.33 | 138 | 0 |
2 | LipE-80 | 10 | 7 | - | - | - | 2.86 | 187 | 14 |
3 | LipE-80 | 9 | 7 | PF68 | 1 | 29 | 1.77 | 177 | 18.4 |
4 | Ph 100H | 2 | 6 | Tw80 | 2 | 15 | 1.04 | 180 | 8.4 |
Above-mentioned preparation be with the amounts of 200 grams separately in batches in Avestin C-50 18, the 000psi operating pressure down preparation and.Before homogenize, the NaOH that adds 5.5%w/w mannitol and 1N is adjusted in pH value between the 7-8.Granular size is the average volume density of being measured by Malvern Mastersizer.The mean particle size of embodiment 1 during homogenize is 7 μ m-9 μ m.Even showing through granule after 180 times, the data extrapolation still remains in this scope.
The stable embodiment 4 of table 1.2-Cyclosporin A microgranule
Through the preparation after the 211 times processing; Final size is 1.00 μ m
Temperature (℃) the final size of initial size (micron) (micron) natural law
4 1.00 0.81 56
25 1.00 0.80 82
From the above-mentioned data of the embodiment 2 of table 1.2 and embodiment 3 as can be known, Lipoid E-80 is used in combination with Pluronic F68, the total w/w% that makes surface modifier can not obtain stable submicron preparation at 10% o'clock, and the gained system HLB value of these preparations is greater than 9.Embodiment 4 has illustrated and has adopted the appropriate combination of phospholipid and surface modifier that system HLB value is reduced to 8.4 that this just can obtain the stabilization formulations of sub-micron.
Embodiment B
Next studied of the influence of system HLB value to the granular size and the stability of ursodiol microgranule.These experiments (by the prepared in batches of 50 grams with 5.5%w/w mannitol) show when phospholipid is used in combination with one or more surface modifiers, make system HLB value greater than 9 or less than 4 o'clock, gained preparation instability.Yet when the combination of selecting for use system HLB value between 4-9, the gained preparation is a sub-micron, is stable.There is not the controlled trial of surface modifier to be used as with reference to being included yet.
Table 2.1-URSODIOL 10%w/w+2 surface modifier
Embodiment | No. 1, surface modifier | Surface modifier number | Whether stable | |||||||
Kind | %w/w | HLB | Kind | %w/w | HLB | Size (μ m) | Pass | System HLB | ||
1 | - | - | 0 | - | - | 0 | 12.61 | 0 * | 0 | No |
2 | Lip E80 | 2.4 | 7 | - | - | - | 1.40 | 105 | 1.7 | No |
3 | Lip E80 | 6 | 7 | - | - | - | 0.99 | 104 | 4.2 | Be |
4 | Lip E80 | 6 | 7 | PF68 | 2 | 29 | 1.31 | 107 | 10 | No |
5 | Lip E80 | 3.8 | 7 | PF68 | 2 | 29 | 0.99 | 106 | 8.5 | Be |
6 | Lip E80 | 1.6 | 7 | T908 | 0.8 | 31 | 1.15 | 107 | 3.6 | No |
Ursodiol 10%w/w+3 surface modifier
Embodiment | Surface modifier 1 | Surface modifier 2 | Surface modifier 3 | |||||||
Kind, %w/w | HLB | Kind, %w/w | HLB | Kind, %w/w | HLB | Size (μ m) | Pass | System HLB | Whether stable | |
7 | Lip E80,6.1 | 7 | Myrj 52,2 | 16.9 | PF68,1.1 | 29 | 1.35 | 102 | 11.6 | No |
*When not having surface modifier, mixed phase produces too much foam when difficulty, and preparation can't be processed.
The stability of table 2.2-IDD-PTMUrsodiol
Implement 4 ℃ 22 ℃ 40 ℃ of sizes 7 days 3 times
Example (micron) stability stability stability vibration thermal cycle
Natural law size natural law size natural law size
3 0.99 28 1.03 28 1.05 7 1.07 1.05 1.07
5 0.99 28 1.02 28 1.03 7 1.06 1.04 1.09
Can draw following important conclusion from the result of table 2.1 and table 2.2:
The embodiment of table 2.1 1,2 and 3 has illustrated that thereby phospholipid concentration is increased to 2.4%, 6% system HLB value from 0% is increased to 1.7,4.2 result from 0 respectively.Under the situation of embodiment 1, there is not surface modifier, be difficult with medicine and water mixing, and preparation can't be by homogenize.The preparation that has greater than 4 system HLB value is a sub-micron and stable, and other preparation then is not like this.
Embodiment 3 and 4 illustrated when phospholipid concentration and has been fixed on 6%, the concentration of PF 68 is increased to 2% from 0%, thereby system HLB value is respectively 4.2 and 10 result.Preparation with system HLB value of 4-9 is a sub-micron and stable, and other preparation then is not like this.
Embodiment 4 and 5 has illustrated concentration fixed as PF 68 2%, content of phospholipid is reduced to 3.8% from 6%, thereby system HLB value is respectively 10 and 8.5 result.Preparation with system HLB value of 4-9 is a sub-micron and stable, and other preparation then is not like this.
Embodiment 6 and 7 has illustrated the result when system HLB value is outside the 3.9-9 scope: granular size is greater than 1 micron, and the preparation instability.Particularly the system HLB value of embodiment 5 is less than 3.9, and the system HLB value of embodiment 6 is greater than 9.
Embodiment C
Present embodiment has been studied the influence of system HLB value to the granular size and the stability of Benprofibratum.These experiments show when phospholipid is used in combination with one or more surface modifiers, make system HLB value less than 4 o'clock, gained preparation instability.Yet when the combination of selecting for use system HLB value between 4-9, the gained preparation is a sub-micron and stable.There is not the controlled trial of surface modifier to be used as with reference to being included yet.
Table 3.1-Benprofibratum 10%w/w (+5.5%w/w mannitol)
Embodiment | No. 1, surface modifier | No. 2, surface modifier | Whether stable | |||||||
Kind | %w/w | HLB | Kind | %w/w | HLB | Size (μ m) | Pass | System HLB | ||
1 | - | - | 0 | - | - | 0 | 65 | 0 * | 0 | No |
2 | Lip E80 | 3 | 7 | - | - | 0 | 1.06 | 70 | 2.1 | No |
3 | Lip E80 | 4 | 7 | - | - | 0 | 0.95 | 70 | 2.8 | No |
4 | Lip E80 | 3 | 7 | PF127 | 1 | 29 | 0.86 | 70 | 5.0 | Be |
5 ** | Ph10OH | 0.83 | 6 | PF108 | 1.67 | 29 | 0.85 | 84 | 5.3 | Be |
6 ** | Ph100H | 1.33 | 6 | PF108 | 0.67 | 29 | 0.83 | 70 | 2.7 | No |
Benprofibratum 5%w/w (+5.5%w/w mannitol)
7 | LipE-80 | 2 | 7 | PF127 | 0.5 | 29 | 88 | 70 | 5.7 | Be |
8 | LipE-80 | 2.3 | 7 | PF127 | 0.2 | 29 | 0.91 | 70 | 4.4 | Be |
*When not having surface modifier, mixed phase is when difficulty, and pharmaceutical suspension and can't process preparation on water.
*There is not mannitol to exist.
In the table 3.1 given preparation be with the amounts of 200 grams separately in batches in M110 EH 18, the 000psi operating pressure down preparation and.Before homogenize, the NaOH that adds 1N is adjusted in pH value between the 6-8.Granular size is the average volume density of being measured by Malvern Mastersizer.
The stability of table 3.2-Benprofibratum microgranule
Embodiment | Size (micron) | 4 ℃ of stability | 22 ℃ of stability | 40 ℃ of stability | Vibration in 7 days | |||
Natural law | Size | Natural law | Size | Natural law | Size | |||
4 | 0.86 | 33 | 1.10 | 29 | 1.32 | 8 | 2.31 | 1.27 |
5 | 0.91 | 26 | 1.1 | 26 | 1.29 | 7 | 1.68 | 1.16 |
7 | 0.88 | 29 | 1.01 | 29 | 1.18 | 12 | 2.47 | 1.09 |
8 | 0.91 | 35 | 1.12 | 35 | 1.25 | 7 | 1.4 | 1.04 |
The embodiment of table 3.1 2 and 4 has illustrated that thereby PF 127 concentration are increased to 1%w/w system HLB value from 0% is respectively 2.1 and the result that produced at 5 o'clock.The preparation that has greater than 4 system HLB value is a sub-micron and stable, and other preparation then is not like this.Thereby embodiment 3 and 4 has illustrated the result that the total surface modification agent content of relative quantity that changes Lip E80 and PF 127 is produced when being 4%w/w.The preparation (embodiment 4) that has greater than 4 system HLB value is stable, and system HLB value is then unstable less than 4 preparation (embodiment 3).
The result that embodiment 5 and 6 has been produced when the relative quantity that changes phosphatidase 11 00H and PF 108 has been described: system HLB value is stable greater than 4 preparation (embodiment 5), and system HLB value is then unstable less than 4 preparation (embodiment 6).
Embodiment 7 and 8 is stable sub-micron preparations, and the total content of its surface modifier is 2.5%w/w, and the system HLB value of each preparation is between 4-9.In two kinds of preparations, used the various combination of Lip E80 and PF 127.
Embodiment 3 and 7 illustrated when the weight ratio of Lip E80 remains on 4, and PF 127 is increased to the result who was produced with respect to the weight ratio of medicine at 1 o'clock from 0.System HLB value is respectively 2.8 and 5.7.System HLB value is a sub-micron greater than 4 preparation, is stable, and other preparation is then unstable.
Embodiment D
In the table 4.1 preparation of listed present embodiment be with the amounts of 200 grams separately in batches (22 ℃ following 120 times) in M110 EH under the 18kpsi operating pressure preparation and.Granular size is the average volume density of being measured by Malvern Mastersizer.
Table 4.1-VEX 5%
Embodiment | Surface modifier #1 | Surface modifier #2 | Whether stable | |||||||
Kind | %w/w | HLB | Kind | %w/w | HLB | Size (μ m) | Pass | System HLB | ||
1 | Lip E80 | 0.5 | 7 | PF 108 | 1.0 | 29 | 0.34 | 120 | 6.5 | Be |
Through after 4 weeks, granular size is 0.34 micron, and is identical with initial size under 25 ℃, and this granule is stable thus.
Embodiment in the last table 4.1 has the system HLB value between the 4-9, at room temperature (25 ℃ of following 4 weeks) show good stable.Medicine after the lyophilization (containing the 5%w/w polyvinylpyrrolidone) reconstitutes 0.37 micron, and is identical with initial size basically.In addition, this preparation demonstrates significant bioavailability for Canis familiaris L. and mouse.The bioavailability of Canis familiaris L. is 27%, and the bioavailability of mouse is 33%.
Claims (13)
1. the method for the consumption of a surface modifier of selecting phospholipid surface modifier and one or more surfactants, the medicine that this method is used for obtaining the water insoluble of stable granular size or being slightly soluble in water is at a kind of micron of steady suspension or the stabilising system of sub-micron microgranule, described suspension is prepared by water-bearing media, this method comprises the consumption of selection with respect to the surface modifier of the consumption of the phospholipid surface modifier of drug dose and one or more surfactants, the consumption of the surface modifier of described phospholipid surface modifier and one or more surfactants is defined as " surface modifier j " together, so that the hydrophilic of described system-lipophile equilibrium valve is between 4 to 9, wherein said system hydrophilic-lipophile balance is defined as:
And wherein said system places phial and when sealing, if satisfy in the following condition at least two, then it is stable:
(1) during 4 ℃ of following 4 weeks, the unit weight mean particle size is less than 1.5 μ m;
(2) during 25 ℃ of following 4 weeks, the unit weight mean particle size is less than 1.5 μ m;
(3) during 40 ℃ of following 1 weeks, the unit weight mean particle size is less than 2.5 μ m;
(4) through after the vibration in 7 days, the unit weight mean particle size is less than 1.5 μ m, and wherein phial is put on the vibration table at the ambient room temperature downside, and hunting speed is 100rpm-110rpm; Or
(5) through after 3 thermal cycles, the unit weight mean particle size is less than 1.5 μ m, and one of them circulation is stored down at 40 ℃ and formed in 1-2 days by storing 1-2 days down at 4 ℃.
2. the process of claim 1 wherein that the lipophile equilibrium valve of surface modifier of described surfactant is between 5 to 35.
3. the process of claim 1 wherein that described phospholipid surface modifier is selected from lecithin, soybean phospholipid and combination thereof.
4. the process of claim 1 wherein that described phospholipid surface modifier is desalination, hydrogenant or partially hydrogenated.
5. the process of claim 1 wherein that described phospholipid surface modifier is selected from phosphatidylcholine, PHOSPHATIDYL ETHANOLAMINE, Phosphatidylserine, phosphatidylinositols, phosphatidyl glycerol, phosphatidic acid, lysophosphatide, and combination.
6. the process of claim 1 wherein that the surface modifier of described surfactant is selected from the block copolymer of polyoxyethylene sorbitan fatty acid esters, oxirane and expoxy propane, Myrj 45, adds four-functional group block copolymer, alkyl aryl polyether sulphonic acid ester, Polyethylene Glycol, hydroxypropyl emthylcellulose, polyvinylpyrrolidone and the polyvinyl alcohol that oxirane and expoxy propane obtain in proper order in ethylenediamine.
7. the process of claim 1 wherein that described medicine water insoluble or that be slightly soluble in water is antifungal, immunosuppressant or immune activation agent, antiviral agent, antitumor agent, analgesics or antiinflammatory, antibiotic, Anti-epileptics, anesthetis, hypnotic, tranquilizer, psychosis, psychosis, antidepressant, antianxiety drugs, anticonvulsant, antagonist, neuron blocker, anticholinergic or cholinergic agent, antimuscarinic drug or muscarine medicine, antiadrenergic, antiarrhythmics, antihypertensive, hormone or nutrient.
8. the process of claim 1 wherein that the lipophile equilibrium valve of surface modifier of described surfactant is between 5 to 35.
9. the process of claim 1 wherein that described phospholipid surface modifier is selected from lecithin, soybean phospholipid and combination thereof.
10. the process of claim 1 wherein that described phospholipid surface modifier is desalination, hydrogenant or partially hydrogenated.
11. the process of claim 1 wherein that described phospholipid surface modifier is selected from phosphatidylcholine, PHOSPHATIDYL ETHANOLAMINE, Phosphatidylserine, phosphatidylinositols, phosphatidyl glycerol, phosphatidic acid, lysophosphatide, and combination.
12. the process of claim 1 wherein that the surface modifier of described surfactant is selected from the block copolymer of polyoxyethylene sorbitan fatty acid esters, oxirane and expoxy propane, Myrj 45, adds four-functional group block copolymer, alkyl aryl polyether sulphonic acid ester, Polyethylene Glycol, hydroxypropyl emthylcellulose, polyvinylpyrrolidone and the polyvinyl alcohol that oxirane and expoxy propane obtain in proper order in ethylenediamine.
13. the process of claim 1 wherein that described medicine water insoluble or that be slightly soluble in water is antifungal, immunosuppressant or immune activation agent, antiviral agent, antitumor agent, analgesics or antiinflammatory, antibiotic, Anti-epileptics, anesthetis, hypnotic, tranquilizer, psychosis, psychosis, antidepressant, antianxiety drugs, anticonvulsant, antagonist, neuron blocker, anticholinergic or cholinergic agent, antimuscarinic drug or muscarine medicine, antiadrenergic, antiarrhythmics, antihypertensive, hormone or nutrient.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10920398P | 1998-11-20 | 1998-11-20 | |
US60/109203 | 1998-11-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1337877A CN1337877A (en) | 2002-02-27 |
CN1213733C true CN1213733C (en) | 2005-08-10 |
Family
ID=22326359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998156442A Expired - Fee Related CN1213733C (en) | 1998-11-20 | 1999-11-19 | Method of preparing stable suspension of insoluble microparticles |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1133280A1 (en) |
JP (1) | JP5296954B2 (en) |
KR (1) | KR20010075713A (en) |
CN (1) | CN1213733C (en) |
AU (1) | AU767737B2 (en) |
CA (1) | CA2349202C (en) |
IL (2) | IL143196A0 (en) |
WO (1) | WO2000030615A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4751556B2 (en) * | 2000-02-28 | 2011-08-17 | ジーンシーグス, インコーポレイテッド | Nanocapsule encapsulation system and method |
MY120279A (en) | 2000-05-26 | 2005-09-30 | Pharmacia Corp | Use of a celecoxib composition for fast pain relief |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
FR2819720B1 (en) | 2001-01-22 | 2004-03-12 | Fournier Lab Sa | NEW FENOFIBRATE TABLETS |
GB0119480D0 (en) | 2001-08-09 | 2001-10-03 | Jagotec Ag | Novel compositions |
US20060003012A9 (en) | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
AU2002337692B2 (en) | 2001-09-26 | 2007-09-13 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
UY27939A1 (en) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | COMPOUNDS |
US7828996B1 (en) | 2009-03-27 | 2010-11-09 | Abbott Cardiovascular Systems Inc. | Method for the manufacture of stable, nano-sized particles |
AU2012346594B2 (en) * | 2011-11-30 | 2017-12-21 | Agency For Science, Technology And Research | GM1 ganglioside to Annexin V microparticle polypeptide ratio for biological monitoring |
CN114367383B (en) * | 2022-01-13 | 2024-01-09 | 苏州丰倍生物科技股份有限公司 | Fatty acid ester nano suspension, preparation method and application thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2651680B1 (en) * | 1989-09-14 | 1991-12-27 | Medgenix Group Sa | NOVEL PROCESS FOR THE PREPARATION OF LIPID MICROPARTICLES. |
US5091187A (en) * | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
IL128632A (en) * | 1996-08-22 | 2003-03-12 | Rtp Pharma Corp | Compositions comprising microparticles of water-insoluble substances and method for preparing same |
IL162023A0 (en) * | 1998-03-30 | 2005-11-20 | Rtp Pharma Inc | Compositions containing microparticles of water-insoluble substances and method for their preparation |
ATE259220T1 (en) * | 1998-05-29 | 2004-02-15 | Skyepharma Canada Inc | MICROPARTICLES PROTECTED AGAINST HEAT AND METHOD FOR THE TERMINAL STEAM STERILIZATION OF SAME |
-
1999
- 1999-11-19 WO PCT/US1999/027435 patent/WO2000030615A1/en not_active Application Discontinuation
- 1999-11-19 EP EP99960497A patent/EP1133280A1/en not_active Ceased
- 1999-11-19 IL IL14319699A patent/IL143196A0/en unknown
- 1999-11-19 CA CA2349202A patent/CA2349202C/en not_active Expired - Fee Related
- 1999-11-19 KR KR1020017006123A patent/KR20010075713A/en not_active Application Discontinuation
- 1999-11-19 JP JP2000583499A patent/JP5296954B2/en not_active Expired - Fee Related
- 1999-11-19 AU AU17374/00A patent/AU767737B2/en not_active Ceased
- 1999-11-19 CN CNB998156442A patent/CN1213733C/en not_active Expired - Fee Related
-
2001
- 2001-05-17 IL IL143196A patent/IL143196A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL143196A0 (en) | 2002-04-21 |
EP1133280A1 (en) | 2001-09-19 |
CA2349202A1 (en) | 2000-06-02 |
WO2000030615A1 (en) | 2000-06-02 |
AU767737B2 (en) | 2003-11-20 |
CA2349202C (en) | 2012-06-19 |
KR20010075713A (en) | 2001-08-09 |
AU1737400A (en) | 2000-06-13 |
CN1337877A (en) | 2002-02-27 |
JP5296954B2 (en) | 2013-09-25 |
JP2002530320A (en) | 2002-09-17 |
IL143196A (en) | 2012-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1303985C (en) | Compositions comprising microparticles of water-insoluble substances and method for preparing same | |
CN1303278B (en) | Method for preparing compositions of microparticles of water-insoluble substances | |
US8206746B2 (en) | Microparticles of water-insoluble substances | |
CN1213733C (en) | Method of preparing stable suspension of insoluble microparticles | |
US6337092B1 (en) | Composition and method of preparing microparticles of water-insoluble substances | |
CN1905905A (en) | High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products | |
CN1794975A (en) | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug | |
AU743917B2 (en) | Compositions comprising microparticles of water-insoluble substances | |
CN1764438A (en) | Methods and apparatuses for the comminution and stabilization of small particles | |
MXPA99001691A (en) | Compositions comprising microparticles of water-insoluble substances and method for preparing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
C10 | Entry into substantive examination | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050810 Termination date: 20151119 |